$BAYZF News

Last published 2w ago

2w agoBAYRY BAYZFBayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet® (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual MeetingBusiness WireLynkuet® (elinzanetant) 60 mg capsules is a neurokinin 1 (NK1) receptor and NK3 receptor antagonist FDA-approved for the treatment of moderate to severe vasomotor symptoms (VMS), also known as hot flashes, due to
2w agoBAYRY BAYZFESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of RecurrenceBusiness WireInterim analysis results from the Phase III DASL-HiCaP trial show a statistically significant 58% reduction in the risk of metastasis or death with NUBEQA® (darolutamide) versus placebo in addition to androgen
1mo agoBAYRY BAYZFBayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific MeetingBusiness WireData from Bayer’s cardiovascular portfolio in heart failure and cardiac amyloidosis will be presented, including late-breaking data for investigational iodine 124 evuzamitide (I 124 evuzamitide) from a Phase III study
1mo agoBAYRY BAYZFActress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to MenopauseBusiness WireBayer and actress Melissa Joan Hart are partnering to raise awareness about Lynkuet® (elinzanetant) 60mg capsules, a hormone-free prescription treatment for the reduction of moderate to severe hot flashes due to
1mo agoBAYRY BAYZFU.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without DiabetesBusiness WireThe supplemental New Drug Application (sNDA) was supported by results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with chronic kidney disease (CKD) without diabetes who were also
1mo agoBAYRY BAYZFBayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United StatesBusiness WireCompany plans to build state-of-the-art site in New Albany, Ohio, U.S., to serve patients in the U.S. as well as globally Bayer expects to create around 600 new high-value jobs in the area Multi-year investment
1mo agoBAYRY BAYZFAlka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold AisleBusiness WireAlka-Seltzer Plus® will relaunch in 2026 as Alka-Seltzer™ Cold, introducing a more intuitive brand architecture, simplified packaging and value-focused options designed to make the cough/cold aisle easier to shop. The
1mo agoBAYRY BAYZFMiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener OptionBusiness WireBayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX® with the active ingredient docusate sodium designed to help gently soften hard, dry stools and support more
1mo agoBAYRY BAYZFU.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast CancerBusiness WireBayer’s supplemental New Drug Application (sNDA) is based on results from the Phase III OASIS-4 investigational study for the treatment of moderate to severe vasomotor symptoms in women receiving endocrine therapy for
1mo agoBAYRY BAYZFRobigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce CostsBusiness WireRobigo’s engineered microbes for combatting Sudden Death Syndrome in soybeans match the performance of commercially available chemistries at half the cost, targeting launch in 2028. The second product in
1mo agoBAYRY BAYZFBayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 DiabetesBusiness WireKERENDIA® (finerenone), a non-steroidal mineralocorticoid receptor antagonist (MRA), is the first new treatment in more than 30 years approved by the FDA for adult patients with chronic kidney disease (CKD) associated
2mo agoBAYRY BAYZFBayer Launches Nationwide Science Delivers Tour to Take Science on the RoadBusiness WireInteractive mobile experience champions evidence-based science, fights misinformation and connects with communities in support of the future of innovation Bayer kicks off a multi-year, nationwide "Science
2mo agoBAYRY BAYZFU.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung CancerBusiness WireFirst-line approval of HYRNUO® (sevabertinib) for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) follows U.S. Food and Drug Administration (FDA) Priority Review and Breakthrough Therapy
2mo agoBAYRY BAYZFBAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATIONBusiness WireGIRK4 (BAY 3670549) is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor being evaluated as a potential new approach to control the electrical activity of
2mo agoBAYRY BAYZFBayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026Business WirePhase III results in patients with suspected cardiac amyloidosis were presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The Journal of the American Medical
2mo agoBAYRY BAYZFBayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026Business WirePresentations include investigational late-breaking KERENDIA® (finerenone) data in chronic kidney disease (CKD), including a pooled analysis from studies in patients with and without diabetes and a subanalysis in
2mo agoBAYRY BAYZFLYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast CancerBusiness WireExpanded authorization introduces a treatment option for women experiencing moderate to severe hot flashes and/or night sweats caused by adjuvant endocrine therapy (AET) related to breast cancer LYNKUET® is the
3mo agoBAYRY BAYZFOne A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg BiotinBusiness WireNew Formula Delivers Daily Nutritional Support for Hair, Skin and Nails* Key Facts One A Day® Women's Multi Gummy vitamins new formula, now with 1,000 mcg of Biotin, and Vitamins A, C, E and Zinc, provides
3mo agoBAYRY BAYZFNew Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems MattersBusiness WireNew research by Economist Enterprise, supported by Bayer, highlights the potential of self-care to become a more integrated component of modern health systems The research underscores that self-care works best when
3mo agoBAYRY BAYZFBayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical TrialsBusiness WireHenry Ford Health selected as one of only four U.S. academic health systems in Bayer’s strategic research network Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership
4mo agoBAYRY BAYZFThe University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical TrialsBusiness WireBayer’s first academic medical center alliance for clinical trial collaboration is designed to accelerate medical discovery and expand patient access to investigational therapies Bayer, a global life sciences
4mo agoBAYRY BAYZFLuke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at WalmartBusiness WireOne A Day®, the multivitamin and supplement brand from Bayer, has partnered with country superstar and five time Entertainer of the Year Luke Bryan to launch a limited edition multivitamin bottle featuring the singer.
4mo agoBAYRY BAYZFBayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as RuveonBusiness WireAdvances key component of Crop Science division’s Five-Year Framework strategy Reinforces commitment to delivering trusted Roundup® brands and glyphosate products and services to U.S. customers Bayer Group today
4mo agoBAYRY BAYZFBayer and Iambic Collaborate to Advance Drug Discovery with AIBusiness WireCollaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’s research and development portfolio by harnessing AI
4mo agoBAYRY BAYZFBayer Welcomes Kacy Perry as New Country Division Head for Crop Science CanadaBusiness WireThe Crop Science division of Bayer announced that Kacy Perry has been appointed the Country Division Head (CDH) for Crop Science Canada, effective July 1. In this role, she will lead 550+ employees working at multiple
4mo agoBAYRY BAYZFBayer Completes Acquisition of Perfuse TherapeuticsBusiness WireBayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now holds the full rights
4mo agoBAYRY BAYZFAleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain ReliefBusiness WireKey Facts Campaign: Project DIY is a new campaign under Aleve's recently launched Feel Aleve® platform. Project DIY showcases how, when home improvement projects are interrupted by body pain, Aleve delivers up
4mo agoBAYRY BAYZFBayer's AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body RegionsBusiness WireKey Facts: Bayer's AMBELVIST® (gadoquatrane) becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved in the U.S., with a recommended dose of 0.01 mmol/kg actual body weight
5mo agoBAYRY BAYZFDr. Jost Reinhard Appointed President of Bayer's Radiology BusinessBusiness WireBayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer's Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will report to Stefan
5mo agoBAYRY BAYZFBayer Announces Global Consumer Health Leadership Changes to Accelerate GrowthBusiness WireBayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the company's
5mo agoBAYRY BAYZFPhase III FIND‑CKD Results Show Bayer's KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney DiseaseBusiness WireInvestigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint—adding to a clinical trial program of more than
5mo agoBAYRY BAYZFBayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026Business WirePresentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease. Bayer Summary Bayer today announced that new investigational data
5mo agoBAYRY BAYZFASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head TrialBusiness WirePhase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median
5mo agoBAYRY BAYZFASCO 2026: Bayer to Present New Data Across Oncology PortfolioBusiness WirePrimary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or
5mo agoBAYRY BAYZFBayer's KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney DiseaseBusiness WireIf approved for this investigational new use, KERENDIA® (finerenone), a non-steroidal mineralocorticoid antagonist (MRA), would be the first MRA indicated for adults with type 1 diabetes and chronic kidney
5mo agoBAYRY BAYZFBayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic AttackBusiness WireKEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the primary efficacy outcome of time to first occurrence of ischemic stroke and the primary
5mo agoBAYRY BAYZFU.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung CancerBusiness WireRegulatory submission for first-line use of HYRNUO is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety in patients with advanced HER2-mutated non-small cell lung cancer
6mo agoBAYRY BAYZFAUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate CancerBusiness WirePrimary results from the Phase II ARASEC trial show that NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival (PFS) and overall
6mo agoBAYRY BAYZFBayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through MovementBusiness WireUp to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a campaign focused on helping people better
6mo agoBAYRY BAYZFBayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural CommunitiesBusiness WireCampaign launches with a Walmart community event and food drive in Clovis, CA on May 14 Additional food collection will take place at Luke Bryan Farm Tour stops in Clovis (May 15) and Elk Grove, CA (May 16) Fans
6mo agoBAYRY BAYZFInvestigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac AmyloidosisBusiness WireKEY FACTS The Phase III REVEAL study met its primary endpoints demonstrating sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide) positron emission tomography computed tomography (PET/CT) for the
6mo agoBAYRY BAYZFBayer to Acquire Perfuse Therapeutics to Complement Ophthalmology PipelineBusiness WirePerfuse Therapeutics' investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR) High unmet medical need of patients with
6mo agoBAYRY BAYZFBayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of AsundexianBusiness WireKEY FACTS Two late-breaking presentations from the landmark OCEANIC-STROKE study will provide new insights into ischemic strokes that occurred during the trial, as well as the net clinical benefit
6mo agoBAYRY BAYZFNew Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is ChangingBusiness WireThe Latest Breakthrough Study from Leaps by Bayer and BCG reveals why optimism varies by technology, region, and context, with varying trends in China, Germany, and the US Younger generations experience the
7mo agoBAYRY BAYZFBayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural ClassBusiness WireBayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new school is dedicated to help improve primary care and the
7mo agoBAYRY BAYZFBayer Announces Leadership Change Within Pharmaceuticals' Worldwide Markets Organization in the U.S. to Support Company's Full Growth PotentialBusiness WireNelson Ambrogio appointed to lead U.S. pharmaceuticals business, Bayer's largest pharmaceutical growth market Appointment supports Bayer Pharmaceuticals' strategy to renew top-line growth and maximize the value of
7mo agoBAYRY BAYZFBayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" InitiativeBusiness WireBayer challenges industry to redefine canola innovation and reframe canola's future around real, lasting systems. Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to
7mo agoBAYRY BAYZFMultiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be LudacrisBusiness WireThe social-first campaign humorously tackles extreme wellness trends while showcasing how Ludacris incorporates One A Day® multivitamins into his daily routine for a simple and attainable approach to support his
8mo agoBAYRY BAYZFBayer Crop Science Launches 2026 Opportunity Scholarship ProgramBusiness WireBayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary education in
8mo agoBAYRY BAYZFKERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney DiseaseBusiness WireKERENDIA® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline to Month 32 – a surrogate